Integrin-Targeted Nanoparticle Drug Delivery Systems

Integrin-targeted nanoparticle drug delivery systems harness the specificity of cell-surface receptors to improve the precision and efficacy of therapeutic agents. Integrins are transmembrane heterodimers that mediate cell adhesion, signalling and migration through recognition of the tripeptide motif Arg-Gly-Asp (RGD). By decorating nanoscale carriers—such as polymeric micelles, liposomes, iron oxide particles or hybrid polymer–inorganic assemblies—with RGD peptides or their analogues, it is possible to promote selective binding to integrin subtypes (notably αvβ3 and αvβ5) overexpressed on tumour vasculature and malignant cells. This active targeting enhances cellular uptake via receptor-mediated endocytosis, increases intratumoural accumulation beyond the passive enhanced permeability and retention (EPR) effect and reduces off-target toxicity. A diversity of materials has been explored, including biodegradable poly(lactic-co-glycolic acid) (PLGA) cores, polyethylene glycol (PEG) shells for extended circulation, and self-assembling peptide frameworks for theranostic applications. Globally, integrin-targeted nanomedicines have shown promise across a spectrum of tumour types, from glioblastoma to osteosarcoma, and in imaging modalities such as magnetic resonance and fluorescence. Continued optimisation of ligand valency, nanoparticle architecture and linker chemistry is driving these platforms towards clinical translation and personalised oncology.

Research from Nature Portfolio

A foundational study described RGD-functionalised PLGA–chitosan nanoparticles loaded with paclitaxel for αvβ3-mediated delivery in lung cancer models, demonstrating enhanced receptor-dependent uptake, G2/M cell-cycle arrest and selective cytotoxicity with reduced effects on non-malignant bronchial cells. The same nanoparticle platform was later adapted to carry cisplatin, highlighting the versatility of this design for drugs with varying solubility and mechanistic profiles.

Integrin-Targeted Nanoparticle Drug Delivery Systems publication trend

The graph below shows the total number of articles in integrin-targeted nanoparticle drug delivery systems across all publications each year (not limited to Nature Index journals).

Technical terms

Integrin αvβ3: Transmembrane receptor overexpressed in angiogenic endothelium and certain tumours, recognising RGD sequences to mediate cell adhesion and internalisation.

RGD peptide: Short tripeptide (Arg-Gly-Asp) motif used as a targeting ligand for integrin receptors.

Polymeric micelle: Nanoscale assembly of amphiphilic block copolymers that encapsulates hydrophobic drugs within a core surrounded by a hydrophilic shell.

Enhanced permeability and retention (EPR) effect: Passive accumulation of nanoparticles in tumour tissue due to leaky vasculature and poor lymphatic drainage.

Theranostics: Integrated approach combining therapeutic and diagnostic functions in a single nanoparticle platform.

References

1. Novel strategies for enhanced fluorescence visualization of glioblastoma tumors based on HPMA copolymers conjugated with tumor targeting and/or cell‐penetrating peptides. View (2024).
2. Multimeric RGD-Based Strategies for Selective Drug Delivery to Tumor Tissues. Pharmaceutics (2023).
3. RGD-tagging of star-shaped PLA-PEG micellar nanoassemblies enhances doxorubicin efficacy against osteosarcoma. International Journal of Pharmaceutics (2024).
4. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Scientific Reports (2017).
5. Molecular Magnetic Resonance Imaging of AngiogenesisIn Vivousing Polyvalent Cyclic RGD-Iron Oxide Microparticle Conjugates. Theranostics (2015).
6. RGD-based self-assembling nanodrugs for improved tumor therapy. Frontiers in Pharmacology (2024).